Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a data partnership on April 14, 2026 to analyze 100,000 whole genomes from pediatric patients.

Rhea-AI Summary

Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a data partnership on April 14, 2026 to analyze 100,000 whole genomes from pediatric patients. The cloud-based platform uses DRAGEN v4.4 and Illumina Connected Analytics to enable cross-cohort, real-time genomic discovery for pediatric cancer and rare disease.

The unified dataset will be available via the Kids First Data Resource Center and support ARPA-H's Pediatric Care eXpansion to link data across >200 pediatric institutions, aiming to accelerate research translation and shorten clinical care timelines.

Positive

• 100,000 whole genomes assembled for pediatric research
• Use of DRAGEN v4.4 and Illumina Connected Analytics for scalable analysis
• Kids First DRC distribution expands researcher access
• Support for ARPA-H PCX to connect >200 pediatric institutions

Negative

• None.

Argus Apr 14 session

+2.65% close to close Open Argus

Details

News Market Reaction – ILMN

On Apr 14, the day this news came out, ILMN closed 2.65% above the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Market Context

This announcement highlights Illumina’s push to scale pediatric genomics, with D3b analyzing 100,000...

Analysis

This announcement highlights Illumina’s push to scale pediatric genomics, with D3b analyzing 100,000 whole genomes and data-sharing spanning more than 200 institutions. It extends a recent series of alliances building large genomic and multiomic datasets. Alongside 2025 revenue of $4.34B and non-GAAP EPS of $4.84, the news underscores a strategy centered on software, AI, and cloud platforms. Investors may watch future updates on dataset growth, clinical integration, and monetization of these capabilities.

Key Figures

Whole genomes analyzed: 100,000 whole genomes Pediatric institutions: More than 200 institutions 2025 revenue: $4.34B +5 more

Whole genomes analyzed

100,000 whole genomes

Pediatric patients in D3b–Illumina initiative

Pediatric institutions

More than 200 institutions

Pediatric Care eXpansion (PCX) national data exchange

2025 revenue

$4.34B

2025 revenue, flat year over year per DEF 14A

Non-GAAP operating margin

23.1%

2025, improved from 21.3% per DEF 14A

Non-GAAP diluted EPS

$4.84

2025 EPS, up 16% year over year per DEF 14A

Operating cash flow

$1,079M

2025 operating cash flow per DEF 14A

Free cash flow

$931M

2025 free cash flow per DEF 14A

Share repurchases

About $740M

Capital returned to stockholders in 2025 per DEF 14A

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Earnings date notice

   24h Move

   -2.2%

   Announced timing of Q1 2026 results and earnings call logistics.

2. Apr 02

   Board changes

   24h Move

   +0.6%

   Retirement of three directors and nomination of David P. King.

3. Mar 18

   Oncology collaboration

   24h Move

   +1.8%

   Expanded Labcorp collaboration to broaden access to precision oncology testing.

4. Mar 16

   Preventive genomics deal

   24h Move

   +0.5%

   Consortium with Veritas Genetics to integrate WGS into preventive care.

5. Mar 05

   Genomic alliance expansion

   24h Move

   -0.6%

   Alliance for Genomic Discovery expanded to 312,000 genomes and new proteomics data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cloud-based data platforms, whole genomes, precision medicine, bioinformatics, +4 more

8 terms

cloud-based data platforms technical

"Through cloud-based data platforms, the global research community can unify..."

Cloud-based data platforms are services that store, organize and analyze large amounts of business information on remote computers accessed over the internet, rather than on local machines. Like a shared virtual warehouse and set of tools that any team can tap into, they matter to investors because they can lower costs, scale quickly with use, enable faster decision-making, and often create steady, recurring revenue or competitive advantage for companies that rely on data.

whole genomes medical

"D3b is analyzing 100,000 whole genomes from pediatric patients..."

Whole genomes are a complete readout of an organism’s DNA—the entire instruction manual that guides how cells work, like scanning every page of a blueprint rather than just a few chapters. For investors, access to whole-genome data can unlock new diagnostics, targeted treatments and drug discovery opportunities, create valuable datasets, and drive regulatory and privacy considerations that affect commercial value and risk.

precision medicine medical

"translate findings for pediatric precision medicine."

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

bioinformatics medical

""Genomic datasets like these give researchers powerful insight for precision medicine," said James Han, vice president of Bioinformatics at Illumina."

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

structural variants medical

"DRAGEN algorithms to correct known errors and reveal structural variants..."

Structural variants are large-scale changes in an organism’s DNA—such as missing, extra, flipped, or rearranged chunks of genetic material—that are like tearing out, duplicating, or reshuffling chapters in a book. Investors should care because these changes can drive or explain diseases, alter how well diagnostics and therapies work, and shift the commercial and regulatory outlook for drugs, tests, and gene-based treatments.

DRAGEN v4.4 technical

"The samples are being analyzed with DRAGEN v4.4 and Illumina Connected Analytics..."

dragen v4.4 is a specific release of a high‑speed genomic data processing system used to convert raw DNA sequencing output into usable genetic results. Think of it like upgrading the engine and software in a factory line: it can make analysis faster, more accurate, and cheaper, which matters to investors because improvements can lower operating costs, accelerate product timelines, and strengthen the reliability of diagnostics or research outputs tied to a company’s revenue or regulatory progress.

Illumina Connected Analytics technical

"analyzed with DRAGEN v4.4 and Illumina Connected Analytics (ICA)..."

Illumina Connected Analytics is a cloud-based service that collects, stores and analyzes DNA sequencing data from lab machines, offering tools to run workflows, share results and manage quality and compliance. Think of it as a secure online photo library and editing suite for genetic data that lets labs and clinics process large volumes of information without running heavy local computers. For investors, such a platform can create recurring software revenue, strengthen customer ties, scale usage across customers, and build valuable data and regulatory considerations that affect long-term growth.

real-world patient trajectories medical

"learn from real-world patient trajectories across multiple institutions..."

Real-world patient trajectories are the patterns of how patients actually progress through a disease and respond to treatments over time using routine healthcare data (like medical records and insurance claims), rather than controlled clinical trials. For investors this shows how a therapy performs in everyday practice — think of it as a travel log that reveals whether a new treatment keeps patients on the road to recovery, detours them with side effects, or fails to reach destinations investors expected, which influences sales, reimbursement, and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care.

SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.

Through this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center (Kids First DRC). This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine.

Congenital conditions and cancers are a leading cause of death in children yet critical data are often siloed across institutions. Shared genomic data ecosystems enable researchers and clinicians to compare cases across large cohorts, validate diagnoses, and inform treatment strategies based on prior patient experiences.

"Genomic datasets like these give researchers powerful insight for precision medicine," said James Han, vice president of Bioinformatics at Illumina. "Through advances in data, software, and AI, we are moving toward a future where genomic insights drive faster research breakthroughs."

"We're excited to apply leading-edge software technology against some of the toughest challenges in pediatric cancer and congenital conditions," said Allison Heath, director of Data Technology and Innovation at D3b. "Our goal is to empower researchers to uncover new biological signals and to bring genomic insights into routine clinical decision-making, creating a new standard of care."

The dataset will include whole genomes from patients with rare congenital conditions and cancers, collected through federally-funded programs, including the Kids First DRC and the Children's Brain Tumor Network (CBTN). The samples are being analyzed with DRAGEN v4.4 and Illumina Connected Analytics (ICA) to create a comprehensive dataset with the accuracy, speed, and scale necessary for meaningful, cross-sample insights.

The initial cohort demonstrated the power of DRAGEN algorithms to correct known errors and reveal structural variants that previous bioinformatics tools were unable to identify. Additionally, Illumina is joining D3b in supporting the Pediatric Care eXpansion (PCX) program of the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS). The effort aims to shorten the care journey for patients from months to weeks by expanding data-sharing capabilities across a national data exchange spanning more than 200 pediatric institutions in the United States, providing clinicians with timely and seamless access to previously unattainable health data and insights, enabling them to learn from real-world patient trajectories across multiple institutions and provide more personalized care for each patient.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

About the Center for Data-Driven Discovery in Biomedicine
The Center for Data-Driven Discovery in Biomedicine (D3b) is a global leader in advancing pediatric research through the integration of data science, technology innovation, and collaborative discovery. Established in 2016 to accelerate cures for children with cancer and other complex diseases, D3b builds and operates pioneering cloud-based platforms that connect researchers, clinicians, patients, and advocates worldwide.

Home to transformative initiatives such as the Children's Brain Tumor Network (CBTN), the Gabriella Miller Kids First Data Resource Center (Kids First DRC), and the RADIANT AI project, D3b develops scalable data ecosystems, harmonized biospecimen resources, and next-generation analytics to fuel breakthroughs in diagnosis, treatment, and clinical care. By uniting multi-institutional expertise with open science principles, D3b empowers discoveries that no single institution could achieve on its own.

Guided by the strategy to harness big data and global collaboration, D3b continues to shape the future of precision medicine, ensuring that every child, regardless of disease, geography, or background, benefits from the most advanced research and therapies.

Contacts

Illumina

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

 

View original content:https://www.prnewswire.com/news-releases/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease-302741288.html

SOURCE Illumina, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the scope of Illumina and D3b's April 14, 2026 genomic partnership (ILMN)?

The partnership will analyze 100,000 whole genomes from pediatric patients for cancer and rare disease research. According to Illumina, the dataset will be processed with DRAGEN v4.4 and ICA and made available via the Kids First Data Resource Center for cross-cohort studies.

How will Illumina's DRAGEN v4.4 and Illumina Connected Analytics affect pediatric genomic research (ILMN)?

DRAGEN v4.4 and ICA provide faster, scalable genome processing and improved variant detection. According to Illumina, the tools corrected prior errors and revealed structural variants, enabling larger cross-sample analyses and more reliable discovery for pediatric precision medicine.

What role does the Kids First Data Resource Center play in the ILMN and D3b collaboration?

Kids First DRC will host and share the unified pediatric genomic dataset with researchers and clinicians. According to Illumina, this enables real-time, cross-cohort analysis and broader access to genomic insights for rare disease and pediatric cancer studies.

How does the collaboration between ILMN and D3b support ARPA-H's Pediatric Care eXpansion (PCX)?

Illumina and D3b are joining PCX to expand national pediatric data sharing across institutions. According to Illumina, the effort aims to connect more than 200 pediatric institutions, shortening patient care journeys from months to weeks via timely data access.

Will the ILMN–D3b dataset improve clinical decision-making for pediatric patients?

The dataset aims to inform diagnoses and treatment strategies by enabling case comparisons across large cohorts. According to Illumina, unified genomic data will help clinicians validate diagnoses and apply prior patient trajectories to personalize care.